References
- 1. ALEMPIJEVIC T., DRAGASEVIC S., ZEC S., POPOVIC D., MILOSAVLJEVIC T. Non-alcoholic fatty pancreas disease. Postgrad Med J 2017; 93(1098):226-230.
- 2. SMITS M.M., VAN GEENEN E.J.M. The clinical significance of pancreatic steatosis. Nat Rev Gastroenterol Hepatol 2011; 8(3): 169-177.
- 3. ROMANA B.S., CHELA H., DAILEY F.E., NASSIR F., TAHAN V. Non-alcoholic fatty pancreas disease (NAFPD). A silent spectator or the fifth component of metabolic syndrome? A literature review. Endocrine Metab Immune Disord – Drug Targets 2018; 18(6): 547-554.
- 4. OU H.-Y., WANG C.-Y., YANG Y.-C., CHEN M.-F., CHANG C.-J. The association between nonalcoholic fatty pancreas disease and diabetes. PloSOne 2013; 8(5): e62561.
- 5. OGILVIE R.F. The islands of langerhans in 19 cases of obesity. J. Pathol. Bacteriol. 1993; 37(3): 473-481.
- 6. WANG C., OU H., CHEN M., CHANG T., CHANG C. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. J AmHeart Assoc 2014: 3(1): e000297.
- 7. LESMANA C.R.A., PAKASI L.S., INGGRIANI S., AIDAWATI M.L., LESMANA L.A. Prevalence of non-alcoholic fatty pancreas disease (nafpd) and its risk factors among adult medical check-up patients in a private hospital: a large cross sectional study. BMCGastroenterol. 2015; 15: 174.
- 8. ZHOU J., LI M.L., ZHANG D.D., LIN H.Y., DAI X.H., SUN X.L. et al. The correlation between pancreatic steatosis and metabolic syndrome in a Chinese population. Pancreatology 2016; 16(4): 578-83.
- 9. UYGUN A, KADAYIFCI A, DEMIRCI H, SAGLAM M, SAKIN YS, OZTURK K et al. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur. J. Intern. Med 2015; 26(1): 37-41.
- 10. AL-HADDAD M, KHASHAB M, ZYROMSKI N, PUNGPAPONG S, WALLACE MB, SCOLAPIO J et al. Risk factors for hyperechogenic pancreas on endoscopic ultrasound: a case-control study. Pancreas 2009; 36(6): 672-5.
- 11. SCHWENZER NF, MACHANN J, MARTIROSIAN P, STEFAN N, SCHRAML C, FRITSCHE A et al. Quantification of pancreatic lipomatosis and liver steatosis by MRI: Comparison of in/opposed-phase and spectral-spatial excitation techniques. Invest. Radiol. 2008; 43(5): 330-337.
- 12. HENI M, MACHANN J, STAIGER H, SCHWENZER NF, PETER A, SCHICK F et al. Pancreatic fat is negatively associated with insulin secretion in individuals with impaired fasting glucose and/or impaired glucose tolerance: a nuclear magnetic resonance study. Diabetes. Metab. Res. Rev. 2010; 26(3) 200-205.
- 13. GABORIT B, ABDESSELAM I, KOBER F, JACQUIER A, RONSIN O, EMUNGANIA O, et al. Ectopic fat storage in the pancreas using 1H-MRS: importance of diabetic status and modulation with bariatric surgery-induced weight loss. Int. J. Obes. 2015; 39(3): 480-487.
- 14. VAN GEENEN E.-J.M., SMITS M. M., SCHREUDER T. C.M.A., VAN DER PEET D.L., BLOEMENA E., MULDER C.J.J. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. Pancreas 2010; 39(8): 1185-1190.
- 15. PACIFICO L, DI MARTINO M, ANANIA C, ANDREOLI GM, BEZZI M, CATALANO C et al. Pancreatic fat and β-cell function in overweight/obese children with nonalcoholic fatty liver disease. World J. Gastroenterol. 2015; 21(15): 4688-4695.
- 16. TARGHER G, ROSSI AP, ZAMBONI GA, FANTIN F, ANTONIOLI A, CORZATO F et al. Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. J. Endocrinol. Invest. 2012; 35(8): 748-753.
- 17. LINGVAYI, ESSER V, LEGENDRE JL, PRICE AL, WERTZ KM, ADAMS-HUET B et al. Noninvasive quantification of pancreatic fat in humans. J. Clin. Endocrinol. Metab. 2009; 94(10): 4070-4076.
- 18. ROSSI AP, FANTIN F, ZAMBONI GA, MAZZALI G, RINALDI CA, DEL GIGLIO M. et al. Predictors of ectopic fat accumulation in liver and pancreas in obese men and women. Obesity (Silver Spring). 2011; 19(9): 1747-1754.
- 19. WU W.-C., WANG C.-Y. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc. Diabetol. 2013; 12: 77.
- 20. LI S., SU L., LV G., ZHAO W., CHEN J. Transabdominal ultrasonography of the pancreas is superior to that of the liver for detection of ectopic fat deposits resulting from metabolic syndrome. Medicine (Baltimore) 2017; 96 (37): e8060.
- 21. WENG S., ZHOU J., CHEN X., SUN Y., MAO Z., CHAI K. Prevalence and factors associated with nonalcoholic fatty pancreas disease and its severity in China. Medicine (Baltimore). 2018; 97 (26): e11293.
- 22. LEE SE, JANG JY, LIM CS, KANG MJ, KIM SH, KIM MA et al. Measurement of pancreatic fat by magnetic resonance imaging: predicting the occurrence of pancreatic fistula after pancreatoduodenectomy. Ann. Surg. 2010; 51 (251): 932-936.
- 23. NAVINA S, ACHARYA C, DELANY JP, ORLICHENKO LS, BATY CJ, SHIVA SS et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci. Transl. Med 2011; 3 (107): 107ra110.
- 24. ACHARYA C, CLINE RA, JALIGAMA D, NOEL P, DELANY JP, BAE K et al. Fibrosis reduces severity of acute-on-chronic pancreatitis in humans. Gastroenterology 2013; 145 (2): 466-475.
- 25. SEPE PS, OHRI A, SANAKA S, BERZIN TM, SEKHON S, BENNETT G et al. A prospective evaluation of fatty pancreas by using EUS. Gastrointest. Endosc. 2011; 73 (5): 987-993.
- 26. ACHARYA C., NAVINA S., SINGH V.P. Role of pancreatic fat in the outcomes of pancreatitis. Pancreatology 2014; 14 (5): 403-408.
- 27. ROSSO E, CASNEDI S, PESSAUX P, OUSSOULTZOGLOU E, PANARO F, MAHFUD M et al. The role of "fatty pancreas" and of BMI in the occurrence of pancreatic fistula after pancreaticoduodenectomy. J. Gastrointest. Surg., 2009; 13 (10): 1845-1851.
- 28. TOMITA Y, AZUMA K, NONAKA Y, KAMADA Y, TOMOEDA M, KISHIDA M et al. Pancreatic fatty degeneration and fibrosis as predisposing factors for the development of pancreatic ductal adenocarcinoma. Pancreas 2014; 43 (7): 1032-1041.
- 39. CATANZARO R., CUFFARI B., ITALIA A., MAROTTA F. Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. World J. Gastroenterol. 2016; 22(34): 7660-7675.
- 30. VIRTUE S., VIDAL-PUIG A. It’s not how fat you are, it’s what you do with it that counts. PLoS Biol. 2008; 6(9): e237.
- 31. SKURK T., ALBERTI-HUBER C., HERDER C., HAUNER H. Relationship between adipocyte size and adipokine expression and secretion. J. Clin. Endocrinol. Metab. 2007; 92(3):1023-1033.
- 32. BLÜHER M. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 2009; 117 (06): 241-250.
- 33. SCHA J.E. Lipotoxicity: when tissues overeat. Curr. Opin. Lipidol.2003; 14 (3): 281-287.
- 34. YE J. Mechanisms of insulin resistance in obesity. Front. Med. 2013; 7 (1): 14-24.
- 35. PINNICK K.E., COLLINS S.C., LONDOS C., GAUGUIER D., CLARK A., FIELDING B.A. Pancreatic ectopic fat is characterized by adipocyte infiltration and altered lipid composition. Obesity 2008; 16 (3): 522-530.
- 36. MARKS W.M., FILLY R.A., CALLEN P.W. Ultrasonic evaluation of normal pancreatic echogenicity and its relationship to fat deposition. Radiology 1980; 137 (2): 475-9.
- 37. NGHIEM D.D., OLSON P.R., ORMOND D. The fatty pancreas allograf T anatomopathologic findings and clinical experience. Transplant. Proc. 2004; 36 (4): 1045-1047.
- 38. WALTERS M.N. Adipose atrophy of the exocrine pancreas. J. Pathol. Bacteriol. 1996; 92 (2): 547-557.
- 39. WELLEN K.E., HOTAMISLIGIL G.S. Inflammation, stress, and diabetes. J. Clin. Invest 2005; 115 (5): 1111-1119.
- 40. VAN RAALTE D.H., VAN DER ZIJL N.J., DIAMANT M. Pancreatic steatosis in humans: cause or marker of lipotoxicity? Curr. Opin. Clin. Nutr. Metab. Care 2010; 13 (4): 478-485.
- 41. TSATSOULIS A., MANTZARIS M.D., BELLOU S., ANDRIKOULA M. Insulin resistance: An adaptive mechanism becomes maladaptive in the current environment – An evolutionary perspective. Metabolism 2013; 62 (5): 622-633.
- 42. UNGER R.H., SCHERER P.E. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol. Metab. 2010; 21 (6): 345-352.
- 43. LEE JS, KIM SH, JUN DW, HAN JH, JANG EC, PARK JY et al. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. World J. Gastroenterol. 2009; 15 (15): 1869-1875.
- 44. Then and now: ATP III vs. IV – American College of Cardiology [Online]. Available: https://www.acc.org/latest-in-cardiology/articles/2014/07/18/16/03/then-and-now-atp-iii-vs-iv. [Accessed: 29-Nov-2018].
- 45. MATSUMOTO S, MORI H, MIYAKE H, TAKAKI H, MAEDA T, YAMADA Y et al. Uneven fatty replacement of the pancreas: evaluation with CT. Radiology 1995; 194(2): 453-458.
- 46. KÜHN JP, BERTHOLD F, MAYERLE J, VÖLZKE H, REEDER SB, RATHMANN W et al. Pancreatic steatosis demonstrated at MR imaging in the general population: clinical relevance. Radiology 2015; 276 (1):129-136.
- 47. CHANTAROJANASIRI T., HIROOKA Y., RATANACHU-EK T., KAWASHIMA H., OHNO E., GOTO H. Evolution of pancreas in aging: degenerative variation or early changes of disease? J. Med. Ultrason.2015; 42 (2): 177-183.
- 48. JEONG H.T., LEE M.S., KIM M.-J. Quantitative analysis of pancreatic echogenicity on transabdominal sonography: correlations with metabolic syndrome. J. Clin. Ultrasound 2015; 43 (2): 98-108.
- 49. POLKOWSKI M, JENSSEN C, KAYE P, CARRARA S, DEPREZ P, GINES A et al. Technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical guideline – March 2017. Endoscopy 2017; 49(10): 989-1006.
- 50. CHOI CW, KIM GH, KANG DH, KIM HW, KIM DU, HEO J et al. Associated factors for a hyperechogenic pancreas on endoscopic ultrasound. World J. Gastroenterol. 2010; 16 (34): 4329-34.
- 51. USTUNDAG Y., CEYLAN G., HEKIMOGLU K. Pancreatic hyperechogenicity on endoscopic ultrasound examination. World J. Gastroenterol. 2011; 17 (15): 2061-2062.
- 52. COSGROVE D, PISCAGLIA F, BAMBER J, BOJUNGA J, CORREAS JM, GILJA OH et al. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 2: clinical applications. Ultraschall der Medizin – Eur. J. Ultrasound 2013; 34 (03): 238-253.
- 53. KUWAHARA T, HIROOKA Y, KAWASHIMA H, OHNO E, YOKOYAMA Y, FUJII T et al. Usefulness of endoscopic ultrasonography-elastography as a predictive tool for the occurrence of pancreatic fistula after pancreatoduodenectomy. J. Hepatobiliary. Pancreat. Sci. 2017; 24 (12): 649-656.
- 54. BARRETO S.G., DIRKZWAGER I., WINDSOR J.A., PANDANABOYANA S. Predicting post-operative pancreatic fistulae using preoperative pancreatic imaging: a systematic review. ANZ J. Surg. 2018 [Epub ahead of print].
- 55. MATHUR A, HERNANDEZ J, SHAHEEN F, SHROFF M, DAHAL S, MORTON C et al. Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenocarcinoma. HPB (Oxford). 2011; 13(6): 404-10.
- 56. TRANCHART H, GAUJOUX S, REBOURS V, VULLIERME MP, DOKMAK S, LEVY P et al. Preoperative CT scan helps to predict the occurrence of severe pancreatic fistula after pancreaticoduodenectomy. Ann. Surg. 2012; 256 (1): 139-145.
- 57. ROBERTS K.J., STOREY R., HODSON J., SMITH A.M., MORRIS-STIFF G. Pre-operative prediction of pancreatic fistula: is it possible?, Pancreatology 2013; 13(4) 423-428.
- 58. SAISHO Y, BUTLER AE, MEIER JJ, MONCHAMP T, ALLEN-AUERBACH M, RIZZA RA et al. Pancreas volumes in humans from birth to age one hundred taking into account sex, obesity, and presence of type-2 diabetes. Clin. Anat. 2007; 20(8): 933-942.
- 59. KIM SY, KIM H, CHO JY, LIM S, CHA K, LEE KH et al. Quantitative assessment of pancreatic fat by using unenhanced CT: pathologic correlation and clinical implications. Radiology 2014; 271 (1): 104-112.
- 60. HU H.H., KIM H.-W., NAYAK K.S., GORAN M.I. Comparison of fat–water MRI and single-voxel MRS in the Assessment of hepatic and pancreatic fat fractions in humans. Obesity 2010; 18(4): 841-847.
- 61. LIVINGSTONE RS, BEGOVATZ P, KAHL S, NOWOTNY B, STRASSBURGER K, GIANI G et al. Initial clinical application of modified Dixon with flexible echo times: hepatic and pancreatic fat assessments in comparison with 1H MRS. Magn. Reson. Mater. Physics. Biol. Med. 2014; 27(5): 397-405.
- 62. MA J., SONG Z., YAN F. Detection of hepatic and pancreatic fat infiltration in type II diabetes mellitus patients with IDEAL-Quant using 3.0T MR: comparison with single-voxel proton spectroscopy. Chin. Med. J. (Engl). 2014; 127 (20): 3548-52.
- 63. OLSEN T.S. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. Acta Pathol. Microbiol. Scand. A. 1978; 86A(5): 367-73.
- 64. WONG VW, WONG GL, YEUNG DK, ABRIGO JM, KONG AP, CHAN RS et al. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. Am. J. Gastroenterol. 2014; 109 (4): 589-597.
- 65. YAMAZAKI H, TSUBOYA T, KATANUMA A, KODAMA Y, TAUCHI S, DOHKE M et al. Lack of independent association between fatty pancreas and incidence of type 2 diabetes: 5-year Japanese cohort study. Diabetes Care2016; 39 (10): 1677-1683.
- 66. KIM MK, CHUN HJ, PARK JH, YEO DM, BAEK KH, SONG KH et al. The association between ectopic fat in the pancreas and subclinical atherosclerosis in type 2 diabetes. Diabetes Res. Clin. Pract. 2014; 106 (3): 590-596.
- 67. MATHUR A, PITT HA, MARINE M, SAXENA R, SCHMIDT CM, HOWARD TJ et al. Fatty pancreas. Ann. Surg. 2007; 246 (6): 1058-1064.
- 68. CAVALLINI G., FRULLONI L., VAONA B., DI FRANCESCO V., BOVO P. Is hyperamylasemia related to dyslipidemia? Gastroenterology 1997; 112 (3): 1058-059.
- 69. GULLO L., LUCREZIO L., MIGLIORI M., BASSI M., NESTICÒ V., COSTA P.L. Benign pancreatic hyperenzymemia or Gullo’s syndrome. Adv. Med. Sci. 2008; 53(1): 1-5.
- 70. KHAN N.A., AMIN M.S., ISLAM M.Z. Pancreatic lipomatosis with massive steatorrhea. Mymensingh Med. J. 2011; 20 (4): 712-714.
- 71. LOZANO M, NAVARRO S, PÉREZ-AYUSO R, LLACH J, AYUSO C, GUEVARA MC et al. Lipomatosis of the pancreas: an unusual cause of massive steatorrhea. Pancreas 1988; 3(5): 580-582.
- 72. AUBERT A, GORNET JM, HAMMEL P, LÉVY P, O’TOOLE D, RUSZNIEWSKI P et al. Diffuse primary fat replacement of the pancreas: an unusual cause of steatorrhea. Gastroenterol. Clin. Biol. 2007; 31 (3): 303-306.
- 73. AMBESH P., LAL H. Pancreatic lipomatosis: complete replacement of pancreas by fat. J. Clin. Diagn. Res. 2015; 9 (10): OL01.
- 74. PRASANNA KUMAR H.R., GOWDAPPA H.B., HOSMANI T., URS T. Exocrine dysfunction correlates with endocrinal impairment of pancreas in type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2018; 22 (1): 121-125.
- 75. HARDT PD, HAUENSCHILD A, NALOP J, MARZEION AM, JAEGER C, TEICHMANN J, et al. High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. Pancreatology 2003; 3 (5): 395-402.
- 76. ČABARKAPA V, DJERIĆ M, MITROVIĆ M, KOJIĆ-DAMJANOV S, ISAKOV I, VUKOVIĆ B et al. Fecal pancreatic elastase-1 and erythrocyte magnesium levels in diabetes type 1 and type 2. Magnes. Res. 2018; 31 (1): 1-10.
- 77. TERZIN V, VÁRKONYI T, SZABOLCS A, LENGYEL C, TAKÁCS T, ZSÓRI G et al. Prevalence of exocrine pancreatic insufficiency in type 2 diabetes mellitus with poor glycemic control. Pancreatology 2014; 14 (5): 356-60.
- 78. ESPOSITO K., CHIODINI P., COLAO A., LENZI A., GIUGLIANO D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012; 35 (11): 2402-2411.
- 79. MENDONÇA FM, DE SOUSA FR, BARBOSA AL, MARTINS SC, ARAÚJO RL, SOARES R et al. Metabolic syndrome and risk of cancer: Which link? Metabolism, 2015; 64 (2): 182-189.
- 80. XU M., JUNG X., HINES O.J., EIBL G., CHEN Y. Obesity and pancreatic cancer: overview of epidemiology and potential prevention by weight loss. Pancreas 2018; 47 (2): 158-162.
- 81. MATHUR A, ZYROMSKI NJ, PITT HA, AL-AZZAWI H, WALKER JJ, SAXENA R et al. Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J. Am. Coll. Surg., 2009; 208 (5): 989-94; discussion 994-996.
- 82. MALVEZZI M, CARIOLI G, BERTUCCIO P, BOFFETTA P, LEVI F, LA VECCHIA C et al. European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018; 29 (4): 1016-1022.
- 83. HONKA H, KOFFERT J, HANNUKAINEN JC, TUULARI JJ, KARLSSON HK, IMMONEN H et al. The effects of bariatric surgery on pancreatic lipid metabolism and blood flow. J. Clin. Endocrinol. Metab. 2015; 100 (5): 2015-023.
- 84. HANSEN E.N., TORQUATI A., ABUMRAD N.N. Results of bariatric surgery. Annu. Rev. Nutr. 2006; 26 (1): 481-511.
- 85. CUMMINGS BP, STRADER AD, STANHOPE KL, GRAHAM JL, LEE J, RAYBOULD HE. et al. Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology 2010; 138 (7): 2437-2446.e1.
- 86. MALIN S.K., KASHYAP S.R. Effects of various gastrointestinal procedures on β-cell function in obesity and type 2 diabetes. Surg. Obes. Relat. Dis. 2016; 12 (6): 1213-1219.
- 87. MCCARTY M.F. Complementary measures for promoting insulin sensitivity in skeletal muscle. Med. Hypotheses 1998; 51 (6): 451-464.
- 88. WRÓBEL M.P., MAREK B., KAJDANIUK D., ROKICKA D., SZYMBORSKA-KAJANEK A., STROJEK K. Metformin – a new old drug. Endokrynol. Pol. 2017; 68 (4): 482-496.
- 89. PIRO S., RABUAZZO A.M., RENIS M., PURRELLO F. Effects of metformin on oxidative stress, adenine nucleotides balance, and glucose-induced insulin release impaired by chronic free fatty acids exposure in rat pancreatic islets. J. Endocrinol. Invest. 2012; 35(5): 504-510.
- 90. TAJIMA K, SHIRAKAWA J, OKUYAMA T, KYOHARA M, YAMAZAKI S, TOGASHI Y et al. Effects of metformin on compensatory pancreatic β-cell hyperplasia in mice fed a high-fat diet. Am. J. Physiol. Metab. 2017; 313 (3): E367-E380.
- 91. REIMER R.A., GROVER G.J., KOETZNER L., GAHLER R.J., LYON M.R., WOOD S. Combining sitagliptin/metformin with a functional fiber delays diabetes progression in Zucker rats. J. Endocrinol. 2014; 220 (3): 361-373.
- 92. LEBOVITZ H.E., BANERJI M.A. Insulin resistance and its treatment by thiazolidinediones. Recent Prog. Horm. Res.2001; 56: 265-294.
- 93. DUPLOMB L, LEE Y, WANG MY, PARK BH, TAKAISHI K, AGARWAL AK et al. Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. Biochem. Biophys. Res. Commun. 2004; 313 (3): 594-599.
- 94. SHIMABUKURO M., ZHOU Y.T., LEE Y., UNGER R.H. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J. Biol. Chem. 1998; 273(6): 3547-3550.
- 95. JIA D.M., FUKUMITSU K.I., TABARU A., AKIYAMA T., OTSUKI M. Troglitazone stimulates pancreatic growth in congenitally CCK-A receptor-deficient OLETF rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001; 280 (5): R1332-40.
- 96. ZHANG W., MIAO J., LI P., WANG Y., ZHANG Y. Up-regulation of components of the renin–angiotensin system in liver fibrosis in the rat induced by CCL4. Res. Vet. Sci. 2013; 95 (1): 54-58.
- 97. SOUZA-MELLO V. Hepatic structural enhancement and insulin resistance amelioration due to AT1 receptor blockade. World J. Hepatol. 2017; 9 (2): 74-79.
- 98. SOUZA-MELLO V., GREGÓRIO B.M., CARDOSO-DE-LEMOS F.S., DE CARVALHO L., AGUILA M.B., MANDARIMDE-LACERDA C.A. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin. Sci. (Lond) 2010; 119 (6): 239-250.
- 99. SOUZA-MELLO V., GREGÓRIO B.M., RELVAS-LUCAS B., DA SILVA FARIA T., AGUILA M.B., MANDARIM-DELACERDA C.A. Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice. Pancreas 2011; 40 (5): 715-722.
- 100. YU T, LIU R, LI M, LI X, QIANG O, HUANG W et al. Effects of octreotide on fatty infiltration of the pancreas in high-fat diet induced obesity rats. Wei Sheng Yan Jiu 2014; 43 (2): 186-92.
- 101. GOTOH K, INOUE M, SHIRAISHI K, MASAKI T, CHIBA S, MITSUTOMI K et al. Spleen-derived interleukin-10 downregulates the severity of high-fat diet-induced non-alcoholic fatty pancreas disease. PLoS One 2012; 7 (12): e53154.
- 102. TURNER N, LI JY, GOSBY A, TO SW, CHENG Z, MIYOSHI H et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008; 57 (5): 1414-1418.
- 103. ZHANG Z, ZHANG H, LI B, MENG X, WANG J, ZHANG Y et al. Berberine activates thermogenesis in white and brown adipose tissue. Nat. Commun. 2014; 5 (1): 5493.
- 104. ZHANG Z, ZHANG H, LI B, MENG X, WANG J, ZHANG Y et al. Effects of berberine and cinnamic acid on palmitic acid-induced intracellular triglyceride accumulation in NIT-1 pancreatic β cells. Chin. J. Integr.Med.2016; 22 (7): 496-502.